Regulatory Transition and Clinical Continuity of Desiccated Thyroid Extract: A Strategic Analysis of FDA Policy Evolutions 2025–2026 Regulatory History: The Distinction Between Grandfathered and GRASE Status Desiccated Thyroid Extract (DTE) has been utilized for thyroid hormone replacement since the late 19th century, pre-dating the formal regulatory framework of the U.S. Food and Drug Administration (FDA). […]
Comment: For the last 30 years of practice, I have consistently recommended moving thyroid medication—including Desiccated Thyroid Extract (DTE)—to breakfast rather than fasting, often to the shock of conventional endocrinologists. This was based on original trials showing that coingestion with food reduced absorption, a factor I knew we could safely manage by monitoring the dose. […]
Comment: This is another in a growing group of studies showing a correlation between levothyroxine (synthetic T4) use and increased cancer risk. What makes this analysis particularly compelling is the direct comparison between treated and untreated patients with hypothyroidism. While we must respect the limitations of observational data, we must also be pragmatic: we are […]
Comment: This is a fascinating review of a complex topic. The key clinical pearl here is the paradoxical finding that treatment-induced hypothyroidism (from TKIs/ICPis) often correlates with a favorable prognosis. It underscores the need to closely monitor thyroid function in these patients—not just as a side effect to be managed, but as a potential prognostic […]
Comment: The summary of this review is striking for the apparent disconnect it highlights regarding Desiccated Thyroid Extract (DTE). The authors accurately report that official guidelines universally reject DTE based on theoretical concerns—namely, the lack of FDA oversight and the transient, non-physiological T3 spikes. Yet the clinical data they reviewed tells an entirely different story: […]
Comment: Here we have another publication adding to the growing body of evidence supporting Natural Desiccated Thyroid (NDT) for the subset of patients who remain symptomatic on standard levothyroxine monotherapy. While this article is a “mini-review” and not a large-scale, rigorous RCT, it correctly highlights the crucial clinical reality: patient-reported outcomes and preferences matter. The […]
Comment: This is a powerful meta-analysis that validates what we and our patients have known for decades. The data is clear: patients overwhelmingly prefer combination therapy, and the network meta-analysis highlights that desiccated thyroid extract (DTE) is the most preferred intervention of all. What’s particularly telling is the discrepancy between patient preference and the results […]
Comment: This is a critical review that articulates a frustration many clinicians and patients have long experienced. It provide a strong physiological rationale for why the standard TSH-centric approach is insufficient for a significant portion of our patients. The central takeaway is the biochemical evidence: LT4 monotherapy, even when it normalizes TSH, often fails to […]
Comment: A critical takeaway from this meta-analysis is the comparable safety profile of DTE. The data indicates no significant negative impact on key outcomes such as heart rate or lipid profiles when compared to standard T4 monotherapy. Beyond its safety, a key potential benefit highlighted is its effect on reverse T3 (rT3). Treatment with DTE […]
Comment: This is yet another high-quality, randomized controlled trial that undermines the long-standing bias against Desiccated Thyroid Extract (DTE). The overall finding is clear: for the average hypothyroid patient, DTE is non-inferior—meaning equivalent—to synthetic levothyroxine (LT4) when it comes to quality of life, memory, and depressive symptoms. The most compelling takeaway (although a post hoc […]
